Company / Working Capital
MBX Biosciences, Inc. Working Capital History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$256.2M
FY2024
5-year range
$79.5M / $256.2M
FY2023-FY2024
Trend
+222.2%
vs FY2023
Sector context
#154 of 213
Health Care
What the data says
At $256M, MBX Biosciences, Inc.'s working capital ranks #154 of 213 in the Health Care sector.
Based on SEC 10-K filings.
$256M in FY2024.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#154 of 213 in Health CareTop 72% of 213This company $256.2M Sector average $934.6M
▼
-72.6% below sector average
Key checks
Key Insights
- In FY2024, working capital increased 222.2% year-over-year.
- Ranks #154 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $256.2M | +222.2% |
| FY2023 | $79.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026